ethyl (E)-4-hydroxy-3-methyl-2-butenoate | 65527-85-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl (E)-4-hydroxy-3-methyl-2-butenoate
• 英文别名: ethyl (E)-4-hydroxy-3-methylbut-2-enoate；(E)-ethyl 4-hydroxy-3-methylbut-2-enoate；Ethyl (2E)-4-hydroxy-3-methylbut-2-enoate
• CAS: 65527-85-7
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: GJPOQWCBISWQSP-GQCTYLIASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  ethyl (E)-4-hydroxy-3-methyl-2-butenoate 在 N,N-二甲基丙烯基脲 、 三溴化磷 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.67h， 生成 依曲替酯
  参考文献：
  名称：

  将3,3'-二羟基异戊二烯裁制为羟基二苯乙烯：发现具有增加的抗增殖活性和细胞选择性的白藜芦醇类似物

  摘要：

  根据异戊二烯单元截留策略，“量身定制” 3,3'-二羟基异戊二烯（天然类胡萝卜素），设计了四种新型化合物。其中，最小的分子1（2,3,6,2'，3'，6'-六甲基-4,4'-二羟基-反式-二苯乙烯）精确合成为一锅Stille-Heck串联序列，并通过阻断NCI-H460细胞在G1期的周期介导的选择性抗增殖活性而成为有前途的先导分子。此外，理论计算和细胞摄取实验表明，化合物1具有独特的多甲基化模式显着诱导构象变化脱离平面，并增加其细胞摄取和代谢稳定性。观察结果应有助于合理设计白藜芦醇类抗增殖药。

  DOI：

  10.1002/chem.201403024
• 作为产物：
  描述：

  L-(+)-酒石酸二乙酯 在 sodium tetrahydroborate 、 NaIO₄ on SiO₂ 、 cerium(III) chloride heptahydrate 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 ethyl (E)-4-hydroxy-3-methyl-2-butenoate
  参考文献：
  名称：

  Inhibition of IspH, a [4Fe–4S]²⁺ Enzyme Involved in the Biosynthesis of Isoprenoids via the Methylerythritol Phosphate Pathway

  摘要：

  The MEP pathway, which is absent in animals but present in most pathogenic bacteria, in the parasite responsible for malaria and in plant plastids, is a target for the development of antimicrobial drugs. IspH, an oxygen-sensitive [4Fe-4S] enzyme, catalyzes the last step of this pathway and converts (E)-4-hydroxy-3-methylbut-2-en-1-yl diphosphate (HMBPP) into the two isoprenoid precursors: isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). A crucial step in the mechanism of this enzyme is the binding of the C4 hydroxyl of HMBPP to the unique fourth iron site in the [4Fe-4S](2+) moiety. Here, we report the synthesis and the kinetic investigations of two new extremely potent inhibitors of E. coli IspH where the OH group of HMBPP is replaced by an amino and a thiol group. (E)-4-Mercapto-3-methylbut-2-en-1-yl diphosphate is a reversible tight-binding inhibitor of IspH with K-i = 20 +/- 2, nM. A detailed kinetic analysis revealed that (E)-4-amino-3-methylbut-2-en-1-yl diphosphate is a reversible slow-binding inhibitor of IspH with K-i = 54 +/- 19 nM. The slow binding behavior of this inhibitor is best described by a one-step mechanism with the slow step consisting of the formation of the enzyme-inhibitor (EI) complex.

  DOI：

  10.1021/ja309557s

文献信息

• Asymmetric Reductive Carbocyclization Using Engineered Ene Reductases
  作者：Kathrin Heckenbichler、Anna Schweiger、Lea Alexandra Brandner、Alexandra Binter、Marina Toplak、Peter Macheroux、Karl Gruber、Rolf Breinbauer

  DOI：10.1002/anie.201802962

  日期：2018.6.11

  bearing an electron‐withdrawing group, for example, a carbonyl group. This asymmetric reduction has been exploited for biocatalysis. Going beyond its canonical function, we show that members of this enzyme family can also catalyze the formation of C−C bonds. α,β‐Unsaturated aldehydes and ketones containing an additional electrophilic group undergo reductive cyclization. Mechanistically, the two‐electron‐reduced

  来自老黄酶 (OYE) 家族的烯还原酶可还原带有吸电子基团（例如羰基）的 α,β-不饱和化合物中的 C=C 双键。这种不对称还原已被用于生物催化。除了其典型功能之外，我们还发现该酶家族的成员还可以催化 C−C 键的形成。含有额外亲电基团的 α,β-不饱和醛和酮会发生还原环化。从机制上讲，双电子还原酶辅因子 FMN 传递氢化物以生成烯醇化物中间体，该中间体与内部亲电子试剂发生反应。用非质子 Phe 或 Trp 单位点取代关键的 Tyr 残基有利于环化反应而不是自然还原反应。新的转化使得对映选择性合成手性环丙烷的效率高达 >99% 。
• Stereoselective Functionalization at C-9 of Retinal: Synthesis of 9-trans-19-Nor-9-haloretinal Analogs.
  作者：Tetsuro SHINADA、Kazuo YOSHIHARA

  DOI：10.1248/cpb.44.264

  日期：——

  Stereoselective functionalization at C-9 of retinal based on the use of the C4+X-unit is described. A sequential linkage of C4+X-units (X=Cl, Br, and I) with ylide 8 (C10) and phosphonate 12 (C5)selectively gave 9-trans-19-nor-9-Cl, Br, and I-retinal derivatives.

  基于C4+X单元的使用，报道了视黄醛C-9位点的立体选择性功能化。通过C4+X单元（X=Cl、Br和I）与亚砜8（C10）和膦酸盐12（C5）的序列连接，选择性地合成了9-反-19-去甲-9-氯、溴和碘-视黄醛衍生物。
• <i>N</i> ‐Heterocyclic Carbene‐Catalyzed Enantioselective Intramolecular Annulations to Construct Benzo‐Fused Pyranones with Quaternary Stereocenter
  作者：Krzysztof Dzieszkowski、Zbigniew Rafiński

  DOI：10.1002/adsc.202000550

  日期：2020.9.21

  intramolecular NHC‐catalyzed approach for the synthesis of benzo‐fused pyranones bearing quaternary stereocenter is described. The developed methodology is based on annulation reaction between acyl anion intermediates and β,β‐disubstituted Michael acceptors. The reaction offers streamlined and effective access to target products in a highly stereoselective manner.

  描述了一种高度对映选择性的分子内NHC催化方法，用于合成带有四级立体中心的苯并稠合吡喃酮。所开发的方法基于酰基阴离子中间体与β，β-二取代的Michael受体之间的环合反应。该反应以高度立体选择性的方式提供了对目标产物的简化有效访问。
• [EN] NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS D'AZAINDOLINE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2019008011A1

  公开（公告）日：2019-01-10

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK - also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及对哺乳动物治疗和/或预防有用的药物，特别是对NF-κB诱导激酶（NIK - 也称为MAP3K14）的抑制剂，用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、包括肥胖和糖尿病在内的代谢性疾病，以及自身免疫性疾病。
• TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20160347717A1

  公开（公告）日：2016-12-01

  Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

  本文披露了化合物或其药学上可接受的盐，以及利用这些化合物治疗乳腺癌的方法，通过向需要治疗的受试者施用这些化合物或其药学上可接受的盐的治疗有效剂量。乳腺癌可能是ER阳性乳腺癌，需要治疗的受试者可能表达突变的ER-α蛋白。